Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3 clinical trials
3 products
Product
RozanolixizumabClinical trial
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Status: Completed, Estimated PCD: 2023-05-11
Product
Efgartigimod PH20 SCProduct
EfgartigimodClinical trial
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Status: Active (not recruiting), Estimated PCD: 2027-03-01